Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Part of paid clinical trials in Fleming Island, Florida.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07215962
Status
Active Not Recruiting

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to assess the treatment-related adverse events and associated healthcare resource use in programmed death ligand 1 (PD-L1) negative individuals diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) who received first-line therapy

Key Dates

Start date
Nov 22, 2024
Status verified
Oct 2025
Primary completion
Jul 1, 2025
Completion
Mar 1, 2026

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Cohort 1
    Participants receiving nivolumab + ipilimumab treatment
  • Arm: Cohort 2
    Participants receiving nivolumab + ipilimumab + platinum-based chemotherapy
  • Arm: Cohort 3
    Participants receiving immuno-oncology therapy (excl nivolumab) with chemotherapy treatment
  • Arm: Cohort 4
    Participants receiving other dual-IO with chemotherapy

Primary Outcome Measure

Incidence of treatment-related adverse events [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Florida Cancer Specialists & Research InstituteFleming IslandFlorida32003-

Find similar trials in Fleming Island, FL

By research site
Florida Cancer Specialists & Research Institute· Fleming Island, FL

Related Studies